EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Serum Neurofilament Light Chain Level as an Indicator of Axonal Injury in Parsonage–Turner Syndrome (Neuralgic Amyotrophy)

Sophie C. Queler, Ek Tsoon Tan, Ari Green, Carlo Milani, Ahmed Abdelhak, Darryl B. Sneag

Journal of the Peripheral Nervous System · 2025-12 · 30 (4)

DOI: 10.1111/jns.70063 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background and Aims Parsonage–Turner syndrome (PTS), also known as neuralgic amyotrophy, is a peripheral neuropathy resulting in severe axonal loss. This study aimed to characterize initial elevation and longitudinal trends of serum neurofilament light chain (sNfL), a marker of neuro‐axonal damage, in PTS. Methods This prospective cohort included 29 adults with electromyography (EMG)–confirmed PTS ≤ 6 months from symptom onset. Patients underwent sNfL testing and EMG at baseline (median 86 days from symptom onset) and again at 3‐ and 6‐month follow‐up intervals. Age‐ and BMI‐adjusted Z ‐scores were analyzed. Linear mixed‐effects models assessed associations between sNfL and time from onset, number of nerves involved, EMG metrics, and corticosteroid use. Results Mean sNfL Z ‐scores were significantly elevated (1.64, SD 1.32, p < 0.001) compared with healthy controls at 0 (1.64, p < 0.001) and 3 months (0.49, SD 1.06, p = 0.020). At 6 months, statistically significant elevations were not detected (0.39, SD 0.96, p = 0.106). sNfL declined by 0.17 Z ‐scores per month (95% CI: 0.11–0.23; p < 0.001). On EMG, the presence of nascent motor units, reflecting reinnervation, was associated with lower sNfL ( p = 0.043). Interpretation sNfL elevation was detected in PTS patients within the first 6 months from symptom onset and decreased as reinnervation ensued. These findings suggest sNfL deserves further consideration as a blood‐based biomarker for detection and monitoring of PTS.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →